New Treatment Option for Chronic Obstructive Pulmonary Disease

Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler

Timothy Self, Samantha Ellingson

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered-dose inhaler was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of 3 delivery systems for LAMA/LABA therapy, including metered-dose inhaler, dry-powder inhaler, and Soft Mist inhaler. On the basis of numerous patient factors, such as cognitive ability, manual strength/dexterity, and peak inspiratory flow, clinicians may select the most appropriate inhalation device. For each inhalation device, persistent patient education is absolutely essential, including observation of patient use. International evidence-based guidelines stress the critical importance of ensuring correct use of inhalation devices.

Original languageEnglish (US)
Pages (from-to)1251-1254
Number of pages4
JournalAmerican Journal of Medicine
Volume130
Issue number11
DOIs
StatePublished - Jan 1 2017

Fingerprint

Metered Dose Inhalers
Nebulizers and Vaporizers
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Muscarinic Antagonists
Glycopyrrolate
Dry Powder Inhalers
Patient Education
Therapeutics
Randomized Controlled Trials
Quality of Life
Observation
Guidelines
Lung

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

New Treatment Option for Chronic Obstructive Pulmonary Disease : Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler. / Self, Timothy; Ellingson, Samantha.

In: American Journal of Medicine, Vol. 130, No. 11, 01.01.2017, p. 1251-1254.

Research output: Contribution to journalReview article

@article{b1af0f64b1f248fc8d470ac1980e765b,
title = "New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler",
abstract = "Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered-dose inhaler was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of 3 delivery systems for LAMA/LABA therapy, including metered-dose inhaler, dry-powder inhaler, and Soft Mist inhaler. On the basis of numerous patient factors, such as cognitive ability, manual strength/dexterity, and peak inspiratory flow, clinicians may select the most appropriate inhalation device. For each inhalation device, persistent patient education is absolutely essential, including observation of patient use. International evidence-based guidelines stress the critical importance of ensuring correct use of inhalation devices.",
author = "Timothy Self and Samantha Ellingson",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.amjmed.2017.07.011",
language = "English (US)",
volume = "130",
pages = "1251--1254",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - New Treatment Option for Chronic Obstructive Pulmonary Disease

T2 - Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler

AU - Self, Timothy

AU - Ellingson, Samantha

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered-dose inhaler was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of 3 delivery systems for LAMA/LABA therapy, including metered-dose inhaler, dry-powder inhaler, and Soft Mist inhaler. On the basis of numerous patient factors, such as cognitive ability, manual strength/dexterity, and peak inspiratory flow, clinicians may select the most appropriate inhalation device. For each inhalation device, persistent patient education is absolutely essential, including observation of patient use. International evidence-based guidelines stress the critical importance of ensuring correct use of inhalation devices.

AB - Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease. Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), and formoterol fumarate is a long-acting beta2 agonist (LABA). In randomized controlled trials, this LAMA/LABA combination in a metered-dose inhaler was shown to be effective in improving pulmonary function and quality of life. Clinicians now have the availability of 3 delivery systems for LAMA/LABA therapy, including metered-dose inhaler, dry-powder inhaler, and Soft Mist inhaler. On the basis of numerous patient factors, such as cognitive ability, manual strength/dexterity, and peak inspiratory flow, clinicians may select the most appropriate inhalation device. For each inhalation device, persistent patient education is absolutely essential, including observation of patient use. International evidence-based guidelines stress the critical importance of ensuring correct use of inhalation devices.

UR - http://www.scopus.com/inward/record.url?scp=85028464244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028464244&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2017.07.011

DO - 10.1016/j.amjmed.2017.07.011

M3 - Review article

VL - 130

SP - 1251

EP - 1254

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 11

ER -